These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 10083128)

  • 1. Pharmacokinetic and safety evaluation of SangCya vs Neoral or Sandimmune in stable renal transplant recipients.
    Gaston R; Alloway RR; Gaber AO; Rossi SJ; Schroeder TJ; Irish WD; Canafax DM; First MR
    Transplant Proc; 1999; 31(1-2):326-7. PubMed ID: 10083128
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetic comparison of two cyclosporine A formulations, SangCya (Sang-35) and Neoral, in stable adult liver transplant recipients.
    Fisher RA; Pan SH; Rossi SJ; Schroeder TJ; Irish WD; Canafax DM; Lopez RR
    Transplant Proc; 1999; 31(1-2):394-5. PubMed ID: 10083157
    [No Abstract]   [Full Text] [Related]  

  • 3. Conversion from cyclosporine Sandimmune to cyclosporine Neoral in the stable renal transplant population.
    Griffin PJ; Moore RH; Jurewicz WA; Lord RH; Webley Y; Jenkins J
    Transplant Proc; 1997; 29(1-2):303. PubMed ID: 9123007
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of conversion from Sandimmune to Neoral on glomerular filtration rate in stable renal transplant recipients.
    Steinmuller D; Dougherty J; Coutee J; Surek D; Swies G; Lewis R
    Transplant Proc; 1997; 29(1-2):298-9. PubMed ID: 9123005
    [No Abstract]   [Full Text] [Related]  

  • 5. Conversion from Sandimmune to Neoral in stable renal transplant recipients. Sandoz Study Group OLN-353.
    Pescovitz MD
    Transplant Proc; 1996 Aug; 28(4):2196-8. PubMed ID: 8769198
    [No Abstract]   [Full Text] [Related]  

  • 6. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral.
    Shah MB; Martin JE; Schroeder TJ; First MR
    Transplant Proc; 1998 Dec; 30(8):4048-53. PubMed ID: 9865291
    [No Abstract]   [Full Text] [Related]  

  • 7. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a Neoral-equivalent cyclosporine formulation, using a dose-adjusted method.
    First MR; Weiskittel P; Shah M; Peddi VR; Canafax D; Schroeder TJ
    Transplant Proc; 1998 Dec; 30(8):3955-7. PubMed ID: 9865260
    [No Abstract]   [Full Text] [Related]  

  • 8. A limited sampling strategy for the estimation of 12-hour SangCya and neoral AUCs in renal transplant recipients.
    Meier-Kriesche HU; Alloway R; Gaber AO; Canafax DM; Kaplan B
    J Clin Pharmacol; 1999 Feb; 39(2):166-71. PubMed ID: 11563409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion to cyclosporine microemulsion (Neoral) in stable renal transplant patients: results from a single center.
    Cossu M; Satta R; Branca GF; Pala PG; Serra G; Satta RP; Sorba G
    Transplant Proc; 1998 Aug; 30(5):1762-3. PubMed ID: 9723271
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis.
    Elder CA; Moore M; Chang CT; Jin J; Charnick S; Nedelman J; Cohen A; Guzzo C; Lowe N; Simpson K
    J Clin Pharmacol; 1995 Sep; 35(9):865-75. PubMed ID: 8786246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic analysis of Neoral conversion in pediatric and adult renal transplant recipients with poor absorption of Sandimmune.
    Pescovitz MD; Henson S; Bodziak K; Book BK; Gonin J; Jindal RM; Leapman SB; Milgrom ML; Filo RS
    Transplant Proc; 1996 Aug; 28(4):2165-8. PubMed ID: 8769189
    [No Abstract]   [Full Text] [Related]  

  • 12. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a novel cyclosporine formulation, using a dose-normalized equivalence method.
    First MR; Weiskittel P; Burton M; Shah M; Dreyer D; Fleck P; Bey C; Peddi R; Canafax D; Schroeder TJ
    Transplant Proc; 1998 Aug; 30(5):1701-5. PubMed ID: 9723249
    [No Abstract]   [Full Text] [Related]  

  • 13. Cyclosporine pharmacokinetics in renal allograft recipients with diabetes mellitus with Sandimmune and Sandimmune Neoral.
    Serafinowicz A; Gaciong Z; Baçzkowska T; Durlik M; Lao M
    Transplant Proc; 1996 Dec; 28(6):3140-1. PubMed ID: 8962217
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of Neoral and Sandimmune preparations in renal transplant patients--improved pharmacokinetics with neoral.
    Warrens AN; Salama A; Waters JB; Lechler RI
    Transplant Proc; 1996 Aug; 28(4):2169-70. PubMed ID: 8769190
    [No Abstract]   [Full Text] [Related]  

  • 15. Can three-times-a-day cyclosporine Neoral avoid cyclosporine toxicity in renal transplant recipients? A pharmacokinetic study.
    Swart N; Botha J; Tandon V; Michaels P; Pontin AR; Halkett J; Pascoe MD; Kahn D
    Transplant Proc; 2001; 33(7-8):3140-1. PubMed ID: 11750349
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients.
    Taesch S; Niese D
    Transpl Int; 1994; 7 Suppl 1():S263-6. PubMed ID: 11271220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, and pharmacokinetics of Sandimmun Neoral: conversion study in stable renal transplant recipients.
    Tsang WK; Ho YW; Tong KL; Chan WH; Chan A
    Transplant Proc; 1996 Jun; 28(3):1330-2. PubMed ID: 8658681
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative pharmacokinetic study of Neoral vs Sandimmun in Japanese stable renal allograft recipients.
    Takahara S; Ohta K; Ohashi Y; Namii Y; Uchida K; Okuyama A; Kainuma H; Takagi H; Takahashi K; Morikawa H
    Transplant Proc; 1999 Nov; 31(7):3089-92. PubMed ID: 10610595
    [No Abstract]   [Full Text] [Related]  

  • 19. Limited sampling strategy to estimate exposure to cyclosporine A in renal allograft recipients treated with Sandimmune-Neoral.
    Serafinowicz A; Gaciong Z; Baçzkowska T; Rell K; Lao M; Wałaszewski J
    Transplant Proc; 1996 Dec; 28(6):3138-9. PubMed ID: 8962216
    [No Abstract]   [Full Text] [Related]  

  • 20. Experience with clinical use of Sandimmun Neoral in renal transplant patients.
    Min ZL; Zhao M; Zhu YH; Qi J; Wang LM; Wang YW
    Transplant Proc; 1996 Jun; 28(3):1356-7. PubMed ID: 8658692
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.